Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bbmt.2014.06.039 http://scihub22266oqcxt.onion/10.1016/j.bbmt.2014.06.039 C4194218!4194218!25017764     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 300.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biol+Blood+Marrow+Transplant 2014 ; 20 (11): 1861-4 Nephropedia Template TP {{tp|p=25017764|t=2014. Prognostic Biomarkers for Acute Graft-Versus-Host-Disease Risk following Cyclophosphamide-Fludarabine Nonmyeloablative Allotransplantation |pdf=|usr=}}{{25017764}} gab.com Text Prognostic Biomarkers for Acute Graft-Versus-Host-Disease Risk following Cyclophosphamide-Fludarabine Nonmyeloablative Allotransplantation JO: Biol Blood Marrow Transplant http://www.kidney.de/pget.php?&tw=1&pmid=25017764 #FOAvip Five candidate plasma biomarkers (ST2, REG3?, elafin, TNFR1, sIL2R?) were measured at specific time-points following cyclophosphamide/fludarabine-based nonmyeloablative allotransplantation (NMAT) in patients who did or did not develop acute graft-versus-host-disease (aGVHD). Plasma samples from 34 patients were analyzed at days +7, +14, +21 and +30. At a median follow-up of 358 days, 17 patients had experienced aGVHD with a median time to onset of day +36. Risk of aGVHD was associated with elevated plasma ST2 concentrations at day +7 (c-stat=0.72, p=0.03), day +14 (c-stat=0.74, p=0.04), and day +21 (c-stat=0.75, p=0.02); elevated plasma REG3? concentrations at day +14 (c-stat=0.73, p=0.03), day +21 (c-stat=0.76, p=0.01) and day +30 (c-stat=0.73, p=0.03); and elevated elafin at day +14 (c-stat=0.71, p=0.04). Plasma concentrations of TNFR1 and sIL2R? were not associated with aGVHD risk at any of the time-points studied. This study identified ST2, REG3? and elafin as prognostic biomarkers to evaluate risk of aGVHD following Cy/Flu-based NMAT. These results need to be confirmed in an independent validation cohort. Twit Text FOAVip Prognostic Biomarkers for Acute Graft-Versus-Host-Disease Risk following Cyclophosphamide-Fludarabine Nonmyeloablative Allotransplantation ????Biol Blood Marrow Transplant http://www.kidney.de/pget.php?&tw=1&pmid=25017764 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25017764 #FOAvip English Wikipedia <ref>{{Cite pmid|25017764}}</ref> Prognostic Biomarkers for Acute Graft-Versus-Host-Disease Risk following Cyclophosphamide-Fludarabine Nonmyeloablative Allotransplantation #MMPMID25017764 Nelson RP; Khawaja MR; Perkins SM; Elmore L; Mumaw CL; Orschell C; Paczesny S Biol Blood Marrow Transplant 2014[Nov]; 20 (11): 1861-4 PMID25017764show ga Five candidate plasma biomarkers (ST2, REG3?, elafin, TNFR1, sIL2R?) were measured at specific time-points following cyclophosphamide/fludarabine-based nonmyeloablative allotransplantation (NMAT) in patients who did or did not develop acute graft-versus-host-disease (aGVHD). Plasma samples from 34 patients were analyzed at days +7, +14, +21 and +30. At a median follow-up of 358 days, 17 patients had experienced aGVHD with a median time to onset of day +36. Risk of aGVHD was associated with elevated plasma ST2 concentrations at day +7 (c-stat=0.72, p=0.03), day +14 (c-stat=0.74, p=0.04), and day +21 (c-stat=0.75, p=0.02); elevated plasma REG3? concentrations at day +14 (c-stat=0.73, p=0.03), day +21 (c-stat=0.76, p=0.01) and day +30 (c-stat=0.73, p=0.03); and elevated elafin at day +14 (c-stat=0.71, p=0.04). Plasma concentrations of TNFR1 and sIL2R? were not associated with aGVHD risk at any of the time-points studied. This study identified ST2, REG3? and elafin as prognostic biomarkers to evaluate risk of aGVHD following Cy/Flu-based NMAT. These results need to be confirmed in an independent validation cohort. äPrognostic Biomarkers for Acute Graft-Versus-Host-Disease Risk followi(epmc).pdf DeepDyve Pubget Overpricing